Trials / Recruiting
RecruitingNCT06961968
Randomized Withdrawal Study in Patients With Schizophrenia
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | iloperidone | iloperidone LAI |
| DRUG | placebo | matching placebo |
Timeline
- Start date
- 2025-05-14
- Primary completion
- 2027-11-01
- Completion
- 2027-11-01
- First posted
- 2025-05-08
- Last updated
- 2026-01-12
Locations
22 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06961968. Inclusion in this directory is not an endorsement.